Production (Stage)
Moleculin Biotech, Inc.
MBRX
$0.67
-$0.0201-2.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.84% | -0.69% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.54% | -6.90% | |||
| Operating Income | 10.54% | 6.90% | |||
| Income Before Tax | -241.98% | 82.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -241.98% | 82.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -241.98% | 82.23% | |||
| EBIT | 10.54% | 6.90% | |||
| EBITDA | 10.59% | 6.91% | |||
| EPS Basic | -84.42% | 86.90% | |||
| Normalized Basic EPS | -84.45% | 86.90% | |||
| EPS Diluted | -84.42% | 86.90% | |||
| Normalized Diluted EPS | -84.45% | 86.90% | |||
| Average Basic Shares Outstanding | 85.41% | 35.68% | |||
| Average Diluted Shares Outstanding | 85.41% | 35.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||